INVASIVE AUTOLOGOUS PLASMIN TREATMENT FOR DIFFUSE DIABETIC MACULAR EDEMA: A PROMISING APPROACH
Main Article Content
Keywords
Acute diabetic macular oedema, autologous plasmin, triamcinolone, and intravitreal injection
Abstract
In one study, IAP injections and triamcinolone acetonide injections are being compared for Diabetic macular edema in diffuse form. 66.4% of the population is older than 64 and 14.4% of the population has diabetes for 14 years or more were measured for the 100 diabetic patients in this study. There were 36 males and 64 females. Two groups of patients were randomly assigned to receive 4 mg TA or 0.2 mL Autologous plasmin freshly prepared after undergoing a full ophthalmologic examination and a full ophthalmologic examination. CMT, BCVA, and IOP were measured at 1, 3, and 6 months to determine the outcome of the study. There was no significant difference between the two groups in the reduction of CMT thickness after TA and plasmin treatment, as both decreased it significantly when compared to baseline thickness. At 6 months after injection, CMT peaked again but remained lower than baseline after 1 month after injection. Plasmin showed less improvement than 1-month measurement and each other. As compared to the BCVA in the IAP group at baseline and at 1 and 3 months, the BCVA in the TA group considerably declined after 6 months. One month after injection versus one month after injection, both groups had lower IOP at 3 and 6 months, although the TA group had a significantly higher IOP, whereas the IAP group did not have a significantly lower IOP. A significant difference was noted between IAP and TA groups in terms of Three- and six-month estimates of IOP. In summary, IAP injections decreased CMT and improved BCVA more effectively than intravitreal injections of TA, and this was safer and longer lasting than intravitreal injections of TA.
References
2. Aiello, L. M. Perspectives on diabetic retinopathy. Am. J. Ophthalmol. 2003, 136, 122–135. https://doi.org/10.1016/S0002-9394(03)00141-3
3. Ciulla, T. A.; Amador, A. G.; Zinman, B. Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies. Diabetes Care 2003, 26, 2653–2664. https://doi.org/10.2337/diacare.26.9.2653
4. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615–1625. https://doi.org/10.2337/diabetes.54.6.1615
5. Pober, J. S.; Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007, 7, 803–815. https://doi.org/10.1038/nri2154
6. Sang, D. N.; D’Amore, P. A. Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 2008, 51, 1570–1573. https://doi.org/10.1007/s00125-008-1093-0
7. Mignatti, P.; Rifkin, D. B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996, 49, 117–137. https://doi.org/10.1002/(SICI)1097-0304(1996)49:2<117::AID-EP16>3.0.CO;2-P
8. Castellino, F. J.; Ploplis, V. A. Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 2005, 93, 647–654. https://doi.org/10.1160/TH04-11-0785
9. Adibhatla, R. M.; Hatcher, J. F. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol. Disord. Drug Targets 2008, 7, 243–253. https://doi.org/10.2174/187152708784389726
10. Lopez-Lopez, F.; Rodriguez-Blanco, M.; Gómez-Ulla, F.; Marticorena, J. Enzymatic vitreolysis. Curr. Diabetes Rev. 2009, 5, 57–62. https://doi.org/10.2174/157339909787021343
11. El-Asrar, A. M.; Al-Mezain, H. S. Pharmacologic vitreolysis in diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12, 406–409. https://doi.org/10.2174/138920111795017439
12. Díaz-Llopis, M.; Udaondo, P.; Arevalo, F.; et al. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J. Ocul. Pharmacol. Ther. 2009, 25, 379–384. https://doi.org/10.1089/jop.2009.0032
13. Rizzo, S.; Pellegrini, G.; Benocci, F.; Belting, C.; Baicchi, M.; Vispi, M. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina 2006, 26, 792–796. https://doi.org/10.1097/01.iae.0000216237.78977.8d
14. Senturk, F.; Ozdemir, H.; Karacorlu, M.; Karacorlu, S. A.; Uysal, O. Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion. Retina 2010, 30, 1254–1261. https://doi.org/10.1097/IAE.0b013e3181d4b69a
15. Khurieva-Sattler, E.; Krause, M.; Löw, U.; et al. Comparison of pars plana vitrectomy with ILM peeling and intravitreal triamcinolone in diffuse diabetic macular edema. Klin. Monbl. Augenheilkd. 2010, 227, 496–500. https://doi.org/10.1055/s-0030-1253006
16. Díaz-Llopis, M.; Udaondo, P.; García-Delpech, S.; Cervera, E.; Salom, D.; Quijada, A. Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema. Arch. Soc. Esp. Oftalmol. 2008, 83, 77–84. https://doi.org/10.1016/S0365-6691(08)70094-2
17. Sakuma, T.; Mizota, A.; Inoue, J.; Tanaka, M. Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. Am. J. Ophthalmol. 2010, 150, 876–882. https://doi.org/10.1016/j.ajo.2010.06.030
18. Udaondo, P.; Díaz-Llopis, M.; García-Delpech, S.; Salom, D.; Romero, F. J. Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion. Arch. Ophthalmol. 2011, 129, 283–287. https://doi.org/10.1001/archophthalmol.2010.370
19. Wilson, C. A.; Berkowitz, B. A.; Sato, Y.; Ando, N.; Handa, J. T.; de Juan, E., Jr. Treatment with intravitreal steroid reduced blood-retinal barrier breakdown due to retinal photocoagulation. Arch. Ophthalmol. 1992, 110(8), 1155–1159. https://doi.org/10.1001/archopht.1992.01080160105037
20. Rangasamy, S.; McGuire, P. G.; Das, A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr. J. Ophthalmol. 2012, 19, 52–59. https://doi.org/10.4103/0974-9233.92792
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Pulgurthi Ramgopal
Assistant Professor, Department Ophthalmology, Sri Lakshmi Narayana Institute of Medical Science, Pondicherry, India.